Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity

Table 2 Copeptin-bivariate correlation analyses (Pearson’s coefficient, *Spearman’s coefficient, copeptin is considered as a continuous variable). Cohort obese individuals (n = 60)

	Correlation coefficient	p value
Age	0.048	0.75
Sex (M/F)	− 0.44	0.001*
BMI	0.03	0.84
Waist circumference	0.03	0.87
SBP (mmHg)	− 0.046	0.76
DBP	− 0.040	0.80
FBG	− 0.25	0.08
Total cholesterol	− 0.06	0.71
HDL	− 0.07	0.65
LDL	0.19	0.23
Triglycerides	− 0.21	0.18
AST	0.13	0.37
ALT	0.27	0.12
Serum creatinine	0.31	0.045
Serum uric acid	0.33	0.045
HOMA-β%	0.05	0.76
HOMA-IR	0.07	0.70
T2DM yes/no	− 0.20	0.15*
MS yes/no	− 0.16	0.29*
NAFL	0.31	0.015*
NASH	0.40	0.002*
NAS: macro-vesicular steatosis	0.36	0.026*
NAS: micro-vesicular steatosis	0.31	0.05*
NAS: lobular inflammation	0.37	0.024*
NAS score	0.35	0.03*
SAF score	0.44	0.001*

Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein, AST aspartate aminotransferase, ALT alanine aminotransferase, FBG fasting blood glucose, FBI fasting blood insulin, HOMA-IR HOmeostasis Model Assessment of insulin resistance, HOMA-β% HOmeostasis Model Assessment of insulin secretion, MS metabolic syndrome, T2DM type 2 diabetes mellitus, NAS NAFLD activity score, SAF steatosis, activity, and fibrosis

ISSN: 1741-7015